(ACAD) ACADIA Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0042251084

Pimavanserin, Trofinetide, Psychosis, Rett Syndrome, CNS Disorders

Biotechnology
Market Cap in USD: 4,531m

IPO / Inception: 2004-05-27
12m vs SPY: 32.5%

EPS (Earnings per Share)

EPS CAGR: 57.52%
EPS Trend: 77.1%

Last SUE: 1.27
Qual. Beats: 1

Revenue

Rev. CAGR: 22.35%
Rev. Trend: 92.8%

Last SUE: 0.22
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	45.9%
Value at Risk 5%th	61.6%
Relative Tail Risk	-18.45%

Reward TTM
Sharpe Ratio	1.12
Alpha	31.83
CAGR/Max DD	0.23

Character TTM
Hurst Exponent	0.480
Beta	0.881
Beta Downside	0.818

Drawdowns 3y
Max DD	57.87%
Mean DD	32.13%
Median DD	33.45%

Description: ACAD ACADIA Pharmaceuticals January 12, 2026

ACADIA Pharmaceuticals (NASDAQ:ACAD) is a U.S.-based biopharma focused on central nervous system (CNS) disorders and rare diseases, commercializing NUPLAZID (pimavanserin) for Parkinson’s disease psychosis and advancing a pipeline that spans schizophrenia, Prader-Willi syndrome, Alzheimer’s-related psychosis, essential tremor, treatment-resistant depression, Rett syndrome, Fragile X, and novel GPR88 agonists.

Key recent metrics: NUPLAZID generated approximately $115 million in net sales in 2023, up ~30 % year-over-year, and the company reported $210 million of cash and marketable securities at the end of Q3 2024, giving it roughly 12-month runway at current burn rates. The Phase III-positive pimavanserin program for negative symptoms of schizophrenia and the Phase III-completed ACP-101 for hyperphagia in Prader-Willi syndrome are the most advanced non-commercial assets.

Sector drivers that materially affect ACAD’s outlook include the growing FDA emphasis on CNS-focused expedited pathways (e.g., Fast Track, Breakthrough Therapy) and the macro-trend of rising investment in rare-disease therapeutics, which typically command premium pricing and limited competition.

Strategic collaborations-such as the Neuren license for trofinetide (Rett syndrome) and the Stoke Therapeutics RNA-medicine partnership-expand ACAD’s platform capabilities while sharing development risk.

For a deeper quantitative view, the ValueRay platform offers a granular breakdown of ACAD’s risk-adjusted valuation.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (261.2m TTM) > 0 and > 6% of Revenue (6% = 62.8m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA -5.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 68.74% (prev 47.82%; Δ 20.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 198.9m <= Net Income 261.2m (YES >=105%, WARN >=100%)

Net Debt (-203.2m) to EBITDA (117.3m) ratio: -1.73 <= 3.0 (WARN <= 3.5)

Current Ratio 3.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.7m) change vs 12m ago 2.69% (target <= -2.0% for YES)

Gross Margin 91.92% (prev 91.61%; Δ 0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 90.75% (prev 95.12%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.61 (EBITDA TTM 117.3m / Interest Expense TTM -170.4m) >= 6 (WARN >= 3)

Altman Z'' -6.26

(A) 0.54 = (Total Current Assets 1.08b - Total Current Liabilities 356.6m) / Total Assets 1.33b

(B) -1.57 = Retained Earnings (Balance) -2.09b / Total Assets 1.33b

warn (B) unusual magnitude: -1.57 — check mapping/units

(D) -5.04 = Book Value of Equity -2.09b / Total Liabilities 413.5m

Total Rating: -6.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 76.14

1. Piotroski 3.0pt

2. FCF Yield 5.29%

3. FCF Margin 18.89%

4. Debt/Equity 0.06

5. Debt/Ebitda -1.73

6. ROIC - WACC (= 1.97)%

7. RoE 32.27%

8. Rev. Trend 92.81%

9. EPS Trend 77.12%

What is the price of ACAD shares?

As of January 15, 2026, the stock is trading at USD 26.86 with a total of 951,832 shares traded.
Over the past week, the price has changed by -2.04%, over one month by -1.47%, over three months by +31.93% and over the past year by +58.93%.

Is ACAD a buy, sell or hold?

ACADIA Pharmaceuticals has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy ACAD.

Strong Buy: 7
Buy: 6
Hold: 6
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the ACAD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	30.7	14.4%
Analysts Target Price	30.7	14.4%
ValueRay Target Price	29.1	8.5%

ACAD Fundamental Data Overview January 12, 2026

P/E Trailing = 17.2774
P/E Forward = 41.3223
P/S = 4.3268
P/B = 4.9393
P/EG = -0.42
Revenue TTM = 1.05b USD
EBIT TTM = 103.2m USD
EBITDA TTM = 117.3m USD
Long Term Debt = 54.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.8m USD (from shortTermDebt, last quarter)
Debt = 54.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -203.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.74b USD (4.53b + Debt 54.8m - CCE 847.0m)
Interest Coverage Ratio = -0.61 (Ebit TTM 103.2m / Interest Expense TTM -170.4m)
EV/FCF = 18.90x (Enterprise Value 3.74b / FCF TTM 197.8m)
FCF Yield = 5.29% (FCF TTM 197.8m / Enterprise Value 3.74b)
FCF Margin = 18.89% (FCF TTM 197.8m / Revenue TTM 1.05b)
Net Margin = 24.94% (Net Income TTM 261.2m / Revenue TTM 1.05b)
Gross Margin = 91.92% ((Revenue TTM 1.05b - Cost of Revenue TTM 84.6m) / Revenue TTM)
Gross Margin QoQ = 92.23% (prev 92.16%)
Tobins Q-Ratio = 2.81 (Enterprise Value 3.74b / Total Assets 1.33b)
Interest Expense / Debt = 16.55% (Interest Expense 9.07m / Debt 54.8m)
Taxrate = 12.25% (31.6m / 258.1m)
NOPAT = 90.6m (EBIT 103.2m * (1 - 12.25%))
Current Ratio = 3.02 (Total Current Assets 1.08b / Total Current Liabilities 356.6m)
Debt / Equity = 0.06 (Debt 54.8m / totalStockholderEquity, last quarter 917.3m)
Debt / EBITDA = -1.73 (Net Debt -203.2m / EBITDA 117.3m)
Debt / FCF = -1.03 (Net Debt -203.2m / FCF TTM 197.8m)
Total Stockholder Equity = 809.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.64% (Net Income 261.2m / Total Assets 1.33b)
RoE = 32.27% (Net Income TTM 261.2m / Total Stockholder Equity 809.4m)
RoCE = 11.95% (EBIT 103.2m / Capital Employed (Equity 809.4m + L.T.Debt 54.8m))
RoIC = 11.19% (NOPAT 90.6m / Invested Capital 809.4m)
WACC = 9.22% (E(4.53b)/V(4.59b) * Re(9.16%) + D(54.8m)/V(4.59b) * Rd(16.55%) * (1-Tc(0.12)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.24%
[DCF Debug] Terminal Value 64.88% ; FCFF base≈199.7m ; Y1≈131.1m ; Y5≈59.8m
Fair Price DCF = 6.91 (EV 965.2m - Net Debt -203.2m = Equity 1.17b / Shares 169.2m; r=9.22% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 77.12 | EPS CAGR: 57.52% | SUE: 1.27 | # QB: 1
Revenue Correlation: 92.81 | Revenue CAGR: 22.35% | SUE: 0.22 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.017 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=0.82 | Chg30d=+0.011 | Revisions Net=+1 | Growth EPS=+0.6% | Growth Revenue=+11.7%

Additional Sources for ACAD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle